Review article · 2017
Conference abstractPublished 27 Oct 2014
Biosimilars-destination in India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
According to the World Bank (2012), 1.237 billion people reside in India, accounting for about 17.5% of the world?s population. India is fast growing from the 15 largest pharmaceutical market in 2007 to 12 in 2011 and is expected to become the 8 largest by 2015. In fact, India?s pharmaceutical market is guided by Increased accessibility and affordability of prescription drugs; An increase in the diagnosis and treatment of chronic diseases.; Mergers, acquisitions and partnerships with big pharmacy ; High growth in the hospital sector. In view of the Biosimilars patents expiry, there is an anticipated surge in the manufacture and serve the people of the country at affordable prices. Biologics are an important component of the pharmaceutical industry and have grown exponentially in the last decade. In recent years, the pharmaceutical industry has placed greater and greater emphasis on developing biopharmaceutical-based drugs (biologics). As a result, the global biologics market is expected to reach $220 billion by 2019. By 2020, patents on several biological products with global sales of more than US$67 billion will expire. Biopharmaceuticals are particularly complex molecules, and biosimilar insulins present special challenges, which is perhaps the most needed by India in the years to come. In part this reflects their structure and chemical modification after synthesis to attain a biologically active form. The manufacturing process for a similar biologic should be highly consistent and robust. If the host cell line used to produce the reference biologic is known, it is preferable to use the same cell line to manufacture the similar biologic. If such a host cell line is not available, any cell line that is adequately characterized and appropriate for intended use can be used to develop the similar biologic. The applicant will need to describe the steps taken to minimize the potential for significant changes in critical quality attributes of the product and to avoid introduction of process related impurities that could impact clinical outcomes and cause immunogenicity issues. The intricacies regarding the vaccine and non-Vaccine products would be reviewed keeping in view of the disease demographic pattern peculiar to India.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 19 Oct 2016
Issues of migrant workers in the context of origin and destination - Evidence from a survey in Coimbatore City, India
Conference abstract · 14 Sep 2012
Incredible India: A case study in strategic destination branding
Conference abstract · 14 Sep 2012
Opportunities, challenges & strategies to market India as a destination to foreign tourists
Article · 2 Jun 2020
Biosimilar 2019 - Development of a male contraceptive from traditionally used Indian medicinal plants - Pratap Chand Mali - University of Rajasthan, India
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “J Sadhana Reddy”

